Opendata, web and dolomites

MMEM SIGNED

Miniaturized Matrixed Enthalpy Metter - Portable, affordable, easy to operate, diagnostic device enabling a rapid & accurate diagnosis of a patient infected by antibiotic-resistant bacteria

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MMEM project word cloud

Explore the words cloud of the MMEM project. It provides you a very rough idea of what is the project "MMEM" about.

rooms    care    isolate    detects    commercial    patient    validation    complicated    made    plans    penetration    entails    tool    internal    diagnosis    detectable    cre    complementary    agreements    displayed    resistance    sensor    gradually    company    genosmart    clinical    israel    device    distributors    electronic    occurs    solid    completion    matrixed    emergency    biologic    start    electric    pyroelectric    meter    labs    kinds    first    form    accurate    detection    ip    facilities    strategic    released    dependency    2020    patients    operator    transduces    techniques    carbapenem    utilizes    immobilized    molecules    rapid    molecular    offices    signal    pilot    fulfills    onto    ultimate    release    bacteria    capability    launch    heat    contrast    dna    miniaturized    antibiotic    laboratories    suspected    reaching    decision    diagnostic    locations    enthalpy    successful    rate    doctor    immediately    point    expansion    market    mmem    energy    resistant    antibiotics    15    pathogenic    sales    bio    hybridization    ready   

Project "MMEM" data sheet

The following table provides information about the project.

Coordinator
GENOSMART LTD 

Organization address
address: 10, JULIELMO MARCONI STREET
city: HAIFA
postcode: 3295524
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙308˙056 €
 EC max contribution 2˙315˙639 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENOSMART LTD IL (HAIFA) coordinator 2˙315˙639.00

Map

 Project objective

Miniaturized Matrixed Enthalpy-Meter (MMEM) - a diagnostic device for a rapid and accurate diagnosis of antibiotic resistant bacteria to be used in emergency rooms, clinical laboratories, doctor offices, and other point-of-care locations. GenoSmart, is developing a novel bio-electronic molecular detection system for detection the presence of a pathogenic DNA is a biologic sample obtained from a patient. In particularly the system allows immediate detection of Carbapenem-resistant bacteria which have developed a resistance to all kinds of known antibiotics. The technology is based on a pyroelectric sensor onto a suspected DNA sample is immobilized. The system utilizes heat release during hybridization of complementary DNA molecules. If a successful hybridization between the sensor and the suspected sample molecules occurs, enthalpy (the internal energy) is released in the form of a detectable heat. The sensor immediately detects this released heat and transduces it to an electric signal. Following this detection, the result is displayed to the operator, and a decision if to isolate the patient from other patients is made. In contrast to currently available molecular detection techniques, GenoSmart MMEM device fulfills the essential need for a rapid and accurate diagnosis tool, along with a cost-effective test and without any dependency on labs and complicated facilities.The ultimate objective is to make GenoSmart's MMEM ready for market launch in Europe. This entails a number of technical and strategic objectives, including the completion of the product’s CRE detection capability, the clinical validation through a European clinical study, and the exploitation of its results (IP expansion, commercial agreements with distributors etc.). The Company plans to start sales in 2020, first in Israel as a pilot market, and gradually reaching solid penetration rate 15% of the CRE diagnosis market within 7 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MMEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MMEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

Genetta (2019)

Pole climbing solution to improve safety at work and to prevent fatal accidents in industrial climbing

Read More  

PestiSi (2019)

Cost effective solution against insects in long-term grain storage by natural diatomaceous earth

Read More